New hope for kids with tough cancers: experimental drug trial begins
NCT ID NCT05608148
Summary
This early-stage trial is testing a new drug called GAIA-102 in children and young adults (ages 1-24) whose cancers have come back or haven't responded to standard treatments. The main goal is to find a safe dose and see how well the body tolerates GAIA-102, both by itself and when combined with other cancer drugs. The study focuses on several aggressive childhood cancers, including neuroblastoma and certain sarcomas.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kyushu University Hospital
RECRUITINGFukuoka, Fukuoka, 812-8582, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.